Related Experiment Video
Updated: Oct 3, 2026

Creating Dynamic Images of Short-lived Dopamine Fluctuations with lp-ntPET: Dopamine Movies of Cigarette Smoking
Published on: August 6, 2013
Any further progress in smoking cessation treatment?
1Department of Psychological Sciences, University of Missouri-Columbia, 65211, USA. PaiseckiT@missouri.edu
Abstract:
The release of the US Public Health Service's quantitative review of smoking treatments, Treating Tobacco Use and Dependence (TTUD; Fiore, Bailey, Cohen et al., 2000, AHRQ Publication, USDHHS), is a fitting occasion to revisit a question posed by Shiffman (1993, Journal of Consulting and Clinical Psychology, 61:718-722): has there been any recent progress in smoking cessation treatment? Using TTUD meta-analyses as a rough guide, we present an overview of current elements of clinical treatments (structure, content, and pharmacotherapy) with statistical claims to efficacy. We note characteristics of treatment, or treatment research, that may retard accumulation of critical knowledge, including the hegemony of multi-component treatments and a seeming disinterest in treatment process. Finally, we sketch avenues of potentially generative research that might foster new insights and improved treatments. It is concluded that not much has changed since Shiffman's (1993) review, and that his call for a rededication to basic research is still prudent but largely unanswered.
Related Concept Videos
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
COPD: Management Using Bronchodilators and Corticosteroids
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Acute Coronary Syndrome IV: Interprofessional Care
COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...